Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

  • Launch across Europe, starting today, strengthens well-established Sandoz immunology portfolio in Europe, leveraging existing footprint
  • Pyzchiva® first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including 130mg vial initiation dose for Crohn’s disease
  • Pyzchiva® to treat adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and pediatric plaque psoriasis

Basel, July 25, 2024 – Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab) across Europe, starting today. Pyzchiva®, developed and registered by Samsung Bioepis, is the first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including the 130mg vial initiation dose for Crohn’s disease.

The launch strengthens our well-established immunology portfolio in Europe and leverages our existing footprint, with five biosimilars now marketed in this therapeutic area. Pyzchiva® is a key biosimilar driver, adding value and contributing to the company’s mid-term growth strategy. 

Rebecca Guntern, President Europe, Sandoz, said: “Timely and expanded access to safe, effective and affordable medicines can improve quality of life for millions of people living with chronic inflammatory diseases. Our goal is to make potentially life-changing medicines accessible to patients across Europe. Pyzchiva® is one of the first ustekinumab biosimilars in Europe, which marks a significant milestone on that road.” 

Pyzchiva® is approved for treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and pediatric plaque psoriasis for patients six years and older weighing over 60 kg.

Europe has the highest prevalence of psoriasis worldwide, affecting an estimated 6.4 million people and significantly impacting patients’ quality of life.1,2 Plaque psoriasis is the most common form of psoriasis, affecting 85% to 90% of patients with psoriasis.3

Sandoz entered into a development and commercialization agreement for biosimilar ustekinumab with Samsung Bioepis in September 2023. Under the terms of the agreement, Sandoz has the right to commercialize Pyzchiva® in the US, Canada, the European Economic Area, Switzerland, and the UK. Samsung Bioepis remains responsible for development, registration, intellectual property, manufacturing, and supply.

*Pyzchiva® is a trademark of Samsung Bioepis Co. Ltd.
**Stelara® is a trademark of Johnson & Johnson

About Pyzchiva® (ustekinumab)
Pyzchiva® (ustekinumab) has been developed as a biosimilar with equivalent efficacy and comparable safety to the reference medicine Stelara®**, a human monoclonal antibody against interleukin (IL)-12/23. Pyzchiva® is approved for treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and pediatric plaque psoriasis for patients six years and older weighing over 60 kg.

Pyzchiva® is available as a 130 mg concentrate in a vial for solution for infusion, additionally, a 90 mg and a 45 mg concentrate solution for injection in a pre-filled syringe.

Disclaimer
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.

References

International Federation of Psoriasis Associations (IFPA). Speaking up for psoriatic disease in Europe. Available at: https://cms.ifpa-pso.com/tools/20072022_IFPA-FORUM_Briefing-Book_Speaking-up.pdf [Last accessed July 2024].Frede N, et al. Psoriasis and Psoriatic Arthritis Have a Major Impact on Quality of Life and Depressive Symptoms: A Cross-Sectional Study of 300 Patients. Rheumatology and Therapy. 2023;10: 1655–1668. doi: 10.1007/s40744-023-00602-9.Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther. 2013;7:201-10.

About Sandoz
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of more than 100 nationalities work together to ensure 800 million patient treatments are provided annually by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the first biosimilar in 2006. In 2023, Sandoz recorded sales of USD 9.6 billion.

Global Media Relations contactsInvestor Relations contacts
Global.MediaRelations@sandoz.comInvestor.Relations@sandoz.com
Joerg E. Allgaeuer
+49 171 838 4838
Karen M. King
+1 609 722 0982
Chris Lewis
+49 174 244 9501
Laurent de Weck
+41 79 795 7364


Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

THỦ THUẬT HAY

Hướng dẫn bạn cách sửa lỗi 0x80070643 trên Windows 11

Người dùng Windows 11 mới đây cho biết, họ gặp phải lỗi cập nhật 0x80070643 khi cài đặt các bản cập nhật vá lỗi mới thông qua Settings. Nếu gặp phải trường hợp đó, hãy khắc phục theo một trong các cách dưới đây.

Tắt các chức năng không cần thiết trên iOS tiêu tốn lượng pin đáng kể

Dung lượng pin trên các máy iPhone đã hạn chế rất nhiều so với các điện thoại Android khác. Đồng thời nếu bạn không thể sở hữu được chiếc iPhone Plus để có dung lượng pin lớn thì việc chiếc iPhone tắt giữa chừng khi

Cách thêm hoặc loại bỏ các tính năng tùy chọn trong Windows 11

Nếu bạn cảm thấy Windows 11 hơi thiếu hoặc thừa các tính năng so với Windows 10 thì dưới đây là cách để bật/tắt một số tính năng khác mà bạn muốn.

Mẹo hay giúp MacBook hoặc iMac có thể nhận cuộc gọi từ iPhone

Có thể bạn chưa biết, Apple đã trang bị cho hệ điều hành macOS tính năng giúp MacBook hoặc iMac có thể nhận cuộc gọi từ iPhone.

Mẹo hay biến iPhone thành webcam của laptop

Đã bao giờ bạn nghĩ đến chuyện tận dụng camera độ phân giải cao của iPhone thay cho webcam chất lượng dở tệ trên laptop. Bạn có thể sử dụng ứng dụng miễn phí iVCam để làm được điều này. Về cơ chế hoạt động, iVCam giúp

ĐÁNH GIÁ NHANH

Đánh giá Vivo Y20s: nhiều ưu điểm vượt trội trong phân khúc 5 triệu

Thuộc phân khúc giá rẻ nhưng Vivo Y20s lại sở hữu nhiều tính năng vượt trội so với các mẫu smartphone cùng phân khúc giá. Để hiểu hơn về chiếc điện thoại này hãy xem giới chuyên môn đánh giá Vivo Y20s như thế nào nhé.

Đánh giá AMD Athlon X4 880K – "Bình mới rượu cũ"

Bên cạnh giải pháp tản nhiệt mới Wraith Cooler, AMD cũng chính thức bán ra thị trường loạt bộ xử lý mới vào đầu tháng Ba vừa qua. Trong đó phổ thông nhất là mẫu Athlon X4 845 có...